Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) EBIT Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has 5 years of EBIT Margin data on record, last reported at 65.61% in Q2 2024.

  • On a quarterly basis, EBIT Margin rose 316698.0% to 65.61% in Q2 2024 year-over-year; TTM through Jun 2025 was 105.97%, a 6582.0% decrease, with the full-year FY2024 number at 27.37%, up 391787.0% from a year prior.
  • EBIT Margin reached 65.61% in Q2 2024 per FULC's latest filing, up from 3213.78% in the prior quarter.
  • Over the last five years, EBIT Margin for FULC hit a ceiling of 65.61% in Q2 2024 and a floor of 9471.19% in Q1 2023.
  • A 5-year average of 2044.08% and a median of 1033.77% in 2020 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: plummeted -846818bps in 2023, then surged 316698bps in 2024.
  • Tracing FULC's EBIT Margin over 5 years: stood at 420.99% in 2020, then fell by -11bps to 465.78% in 2021, then plummeted by -777bps to 4083.65% in 2022, then increased by 21bps to 3213.78% in 2023, then soared by 102bps to 65.61% in 2024.
  • Business Quant data shows EBIT Margin for FULC at 65.61% in Q2 2024, 3213.78% in Q4 2023, and 3615.28% in Q3 2023.